Page 48 - AN-1-1

Advanced Neurology Insights on ARIA

amyloid deposition in Alzheimer’s disease. EMBO Mol Med, 23. Barakos J, Sperling R, Salloway S, et al., 2013, MR imaging
11(12): e11170. features of amyloid-related imaging abnormalities. AJNR
Am J Neuroradiol, 34(10): 1958–1965.
13. Guo T, Korman D, Baker SL, et al., 2021, Longitudinal
cognitive and biomarker measurements support 24. Cummings J, Aisen P, Apostolova LG, et al., 2021,
a unidirectional pathway in Alzheimer’s disease Aducanumab: Appropriate use recommendations. J Prev
pathophysiology. Biol Psychiatry, 89(8): 786–794. Alzheimers Dis, 8(4): 398–410.
http://doi.org/10.1016/j.biopsych.2020.06.029 25. Haeberlein SB, von Hehn C, Tian Y, et al., 2019, EMERGE
and ENGAGE Topline Results: Two Phase 3 Studies to
14. Jack CJ Jr., Wiste HJ, Therneau TM, et al., 2019, Associations Evaluate Aducanumab in Patients With Early Alzheimer’s
of amyloid, tau, and neurodegeneration biomarker profiles Disease. Available from: https://investors.biogen.com/
with rates of memory decline among individuals without static-files/f91e95d9-2fce-46ce-9115-0628cfe96e83 [Last
dementia. JAMA, 321(23): 2316–2325.
accessed on 2022 Mar 16].
15. Jack CR Jr., Bennett DA, Blennow K, et al., 2018, NIA-AA 26. Sperling R, Salloway S, Brooks DJ, et al., 2012, Amyloid-
research framework: Toward a biological definition of related imaging abnormalities in patients with Alzheimer’s
Alzheimer’s disease. Alzheimers Dement, 14(4): 535–562. disease treated with bapineuzumab: A retrospective analysis.
http://doi.org/10.1016/j.jalz.2018.02.018 Lancet Neurol, 11(3): 241–249.
16. Donohue MC, Sperling RA, Petersen R, et al., 2017, http://doi.org/10.1016/S1474-4422(12)70015-7
Association between elevated brain amyloid and subsequent 27. Carlson C, Estergard W, Oh J, et al., 2011, Prevalence of
cognitive decline among cognitively normal persons. JAMA, asymptomatic vasogenic edema in pretreatment Alzheimer’s
317(22): 2305–2316. disease study cohorts from phase 3 trials of semagacestat
http://doi.org/10.1001/jama.2017.6669 and solanezumab. Alzheimers Dement, 7(4): 396–401.
17. Cummings J, Lee G, Zhong K, et al., 2021, Alzheimer’s http://doi.org/10.1016/j.jalz.2011.05.2353
disease drug development pipeline: 2021. Alzheimers 28. Pichler M, Vemuri P, Rabinstein AA, et al., 2017, Prevalence
Dement (NY), 7(1): e12179. and natural history of superficial siderosis: A population
http://doi.org/10.1002/trc2.12179 based study. Stroke, 48(12): 3210–3214.
18. Cummings J, Aisen P, Lemere C, et al., 2021, Aducanumab http://doi.org/10.1161/STROKEAHA.117.018974
produced a clinically meaningful benefit in association with 29. Vernooij MW, van der Lugt A, Ikram MA, et al., 2008,
amyloid lowering. Alzheimers Res Ther, 13(1): 98. Prevalence and risk factors of cerebral microbleeds: The
http://doi.org/10.1186/s13195-021-00838-z Rotterdam scan study. Neurology, 70(14): 1208–1214.
19. Salloway S, Sperling R, Gilman S, et al., 2009, A phase 2 http://doi.org/10.1212/01.wnl.0000307750.41970.d9
multiple ascending dose trial of bapineuzumab in mild 30. Gutt S, Brocco A, Sharma S, 2019, Variability of Aria
to moderate Alzheimer disease. Neurology, 73(24): 2061– Detection in Patients Receiving Monoclonal Antibodies
2070. Against Amyloid-β PLAQUES, Poster Presented at AAIC
20. Jeremic D, Jiménez-Díaz L, Navarro-López JD, 2021, 2019 (P1-045).
Past, present and future of therapeutic strategies against 31. Avgerinos KI, Ferrucci L, Kapogiannis D, 2021, Effects of
amyloid- beta peptides in Alzheimer’s disease: A systematic monoclonal antibodies against amyloid-beta on clinical and
review. Ageing Res Rev, 72: 101496. biomarker outcomes and adverse event risks: A systematic
http://doi.org/10.1016/j.arr.2021.101496 review and meta-analysis of phase III RCTs in Alzheimer’s
disease. Ageing Res Rev, 68: 101339.
21. DiFrancesco JC, Longoni M, Piazza F, 2015, Anti-abeta
autoantibodies in amyloid related imaging abnormalities http://doi.org/10.1016/j.arr.2021.101339
(ARIA): Candidate biomarker for immunotherapy in 32. Ketter N, Brashear HR, Bogert J, et al., 2017, Central review
Alzheimer’s disease and cerebral amyloid angiopathy. Front of amyloid-related imaging abnormalities in two Phase
Neurol, 6: 207. III clinical trials of bapineuzumab in mild-to-moderate
http://doi.org/10.3389/fneur.2015.00207 Alzheimer’s disease patients. J Alzheimers Dis, 57(2): 557–573.
http://doi.org/10.3233/JAD-160216
22. Sperling RA, Jack CR Jr., Black SE, et al., 2011,
Amyloid- related imaging abnormalities in amyloid- 33. Brashear HR, Ketter N, Bogert J, et al., 2018, Clinical
modifying therapeutic trials: Recommendations from the evaluation of amyloid-related imaging abnormalities in
Alzheimer’s association research roundtable workgroup. bapineuzumab phase III studies. J Alzheimers Dis, 66(4):
Alzheimers Dement, 7(4): 367–385. 1409–1424.
http://doi.org/10.1016/j.jalz.2011.05.2351 http://doi.org/10.3233/JAD-180675

Volume 1 Issue 1 (2022) 8 https://doi.org/10.36922/an.v1i1.2